Want to see DWTX full AI Analyst Report?
DWTX Stock Chart & Stats
$1.50
$0.03(2.00%)
At close: 4:00 PM EDT
$1.50
$0.03(2.00%)
Day’s Range― - ―
52-Week Range$1.28 - $9.50
Previous Close$1.53
Volume4.55K
Average Volume (3M)1.54M
Market Cap
$78.52M
Enterprise Value$45.47
Total Cash (Recent Filing)$9.61M
Total Debt (Recent Filing)$127.21K
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Nov 05, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.95
Shares Outstanding33,992,554
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.50Price Target Upside800.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces refinancing needs, interest expense and balance-sheet stress. This gives Dogwood greater financial flexibility while it advances development programs, although it does not resolve the company’s need for funding.
Governance Continuity And OversightContinuity of the board and retention of an independent auditor support organizational stability and financial oversight. These controls can help maintain accountability as the company manages clinical development, reporting obligations and future financing.
Financing FlexibilityExpanded authorization gives Dogwood more capacity to raise capital or pursue strategic transactions needed to fund development. This is important for a pre-revenue biotech, although any equity financing could dilute existing holders.
Bears Say
No Demonstrated Revenue BaseWithout commercial revenue, Dogwood remains dependent on external funding and successful development milestones to create value. The absence of a top-line ramp provides no evidence yet of product-market traction or recurring operating support.
Widening LossesRapidly increasing losses indicate that operating costs and development spending are rising faster than the company’s ability to generate income. Unless the pipeline produces meaningful commercial or partnership returns, profitability may remain several periods away.
Persistent Cash Burn And Funding DependenceSustained negative operating and free cash flow means Dogwood cannot currently fund operations internally. Continued burn increases reliance on equity, debt or strategic funding, potentially limiting negotiating power and creating recurring dilution risk.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.28 and its highest was $9.50 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $78.52M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 76 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.2.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 33,992,554 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 2.857%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.75%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$13.50
▲(800.00% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
72.79% Insiders
0.44% Mutual Funds
9.22% Other Institutional Investors
17.09% Public Companies and
Individual Investors